Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Pint Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO (berotralstat) in Latin America","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"AUSTRIA","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Announces Approval of ORLADEYO (berotralstat) by the Public Health Institute of Chile","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"AUSTRIA","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi\u00ae (ropeginterferon alfa-2b-njft) in Latin America","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"AUSTRIA","productType":"Large molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"OrphanDC","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Empaveli is the First Treatment for PNH that Binds to the Complement Protein C3","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"AUSTRIA","productType":"Peptide","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pint Pharma Announces the Approval of ORLADEYO (berotralstat), the First Oral Therapy Indicated for Preventing Hereditary Angioedema (HAE) Attacks in Adult and Pediatric Patients Aged 12 and Older in Brazil","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"AUSTRIA","productType":"Small molecule","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Pint Pharma

    Menu

    Pint Pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Pint Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Austria
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Pint Pharma Announces the Approval of ORLADEYO (berotralstat), the First Oral Therapy Indicated for Preventing Hereditary Angioedema (HAE) Attacks in Adult and Pediatric Pa...

              Details:

              Orladeyo (berotralstat), an inhibitor of plasma kallikrein, is the first and only oral therapy specifically designed to prevent hereditary angioedema attacks in adult and pediatric patients aged 12 and older.

              Lead Product(s): Berotralstat

              Therapeutic Area: Genetic Disease Product Name: Orladeyo

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: BioCryst Pharmaceuticals

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 16, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Pint Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Austria
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Empaveli is the First Treatment for PNH that Binds to the Complement Protein C3

              Details:

              Empaveli (pegcetacoplan) is the first treatment for PNH that binds to the complement protein C3, which is indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria.

              Lead Product(s): Pegcetacoplan

              Therapeutic Area: Rare Diseases and Disorders Product Name: Empaveli

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: OrphanDC

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 17, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Pint Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Austria
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi® (ropeginterferon alfa-2b-njft) in Latin America

              Details:

              Under the agreement, Pint-Pharma will be obtaining and maintaining all marketing authorizations and commercializing BESREMi (ropeginterferon alfa-2b-njft), the first approved mono-pegylated proline interferon for polycythemia vera, a rare blood cancer, in Latin America.

              Lead Product(s): Ropeginterferon-Alfa-2b

              Therapeutic Area: Oncology Product Name: Besremi

              Highest Development Status: Approved Product Type: Large molecule

              Recipient: PharmaEssentia

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement June 02, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Pint Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Austria
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BioCryst Announces Approval of ORLADEYO (berotralstat) by the Public Health Institute of Chile

              Details:

              Orladeyo® (berotralstat) is the first and only oral therapy designed to prevent attacks of HAE in adult and pediatric patients 12 years and older. One capsule per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.

              Lead Product(s): Berotralstat

              Therapeutic Area: Genetic Disease Product Name: Orladeyo

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: BioCryst Pharmaceuticals

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 22, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Pint Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Austria
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO (berotralstat) in Latin America

              Details:

              Under the terms of the agreement, Pint Pharma will be responsible for obtaining and maintaining all marketing authorizations and for commercializing ORLADEYO in the pan-LATAM region.

              Lead Product(s): Berotralstat

              Therapeutic Area: Genetic Disease Product Name: Orladeyo

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: BioCryst Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership June 09, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY